The Beginnings…

• India was heavily dependent after independence

• Self sufficiency in drugs and pharmaceuticals – need of the hour

• Mr. Ramanbhai B. Patel, quit his job as a lecturer at one of India’s

oldest pharmacy colleges, the L.M. College of Pharmacy to become an

entrepreneur

• He established Cadila Laboratories Ltd., in 1952.

• 1950s & 1960s : Cadila made a mark with innovative medicines and created

enduring brands

• Livirubra – first of its kind in India to treat pernicious anemia • Introduced Isopar – a rational formulation of INH & PAS for the treatment of

tuberculosis.

• Neuroxin-12 was the first of its kind, where incompatible neurotropics – B, B6, B12 were made compatible in a vial.

• Introduced Ampicillin in anhydrous form.

• Received the National Award for import substitution. Develops the process

technology for the anti-diabetic drug Glibenclamide.

• Dexona – 20 is launched for the first time in India to provide Dexamethasone in concentrated form for the treatment of shocks.

• 1970s & 80s : Cadila became a benchmark for Quality and Excellence • Received the award for excellence in Quality from Indian Drug Manufacturers’

Association. • A full-fledged R&D centre set up with recognition from the Department of Science

and Technology, Govt. of India.

• Answering the call to increase exports, the production unit of Cadila Exports was set up at Kandla Free Trade Zone.

• The unit was inaugurated by the former Prime Minister of India, Late Mrs. Indira Gandhi.

• Received the First Award from Chemexcil for it export performance consecutively for two years from 1982-84 and the top award for export performance for the year 1985-86.

• Entered the sphere of beauty care with a range of beauty care products.

Restructuring and establishing our business and creating win-win alliances

1995 - 2000

1995-96 Zydus’ journey began with Rs 250 crs.

1995-96 Acquired Indo Pharma Pharmaceutical Works Ltd- the first acquisition by the group

1995-96 Launched 23 new products in 1995, with first –in-India like Falcigo

1996-97 Registered the fastest growth among the top 80 Pharma companies in India

1997-98 Entered into JV with BYK Gulden, a German pharma major to set up a 50:50 JV. (Byk was renamed as Altana Pharma and was later acquired by Nycomed, which has now been acquired by Takeda).

1999-00 Project Disha led the way to TA focus in Domestic business

1999-00 Entered into Capital markets through - Initial Public offering (IPO)

1999-00 Entered into JV with Sarabhai for consolidating its position in Animal Healthcare

2000-2006

Focusing on operational efficiencies, creating critical mass in the domestic market and foraying into the international market

2000-01 Acquired Recon Healthcare. This move boosted the group’s strengths in southern markets

2000-01 Zydus Research Centre set up at Moraiya

2001-02 Acquired German Remedies; It was then the largest M&A in the Indian Pharmaceutical Sector.

2001-02 Acquired Aten and with it attained the top spot in CVS segment

2001-02 Acquired USFDA approved API plant – Banyan Chemicals

2002-03 DELTA & PRISM initiatives were introduced to institutionalize cost savings & optimal utilization of internal resources

2002-03 Zyfine, a Fine Chemicals division was set up in March 2002 to cater to the need of the industries which requires high purity products for chemical process.

2002-03 Zydus Pharmaceuticals USA Inc. is incorporated

2003-04 First international acquisition by acquiring Alpharma France [renamed as Zydus France]

2004-05 Filed our First IND in India for ZYH1

2005-06 Acquired 30.7% stake in Carnation Nutra Analogue Foods Ltd

Emergence as a global healthcare provider, robust NME

pipeline, thrust on operational efficiencies & continued

focus on domestic business

2006 – 2012

2006-07 Acquired Liva Healthcare & entered dermatology market

2006-07 Acquired Nippon Universal & with it entered the Japanese market

2007-08 Entered into branded generic market of Brazil with the acquisition of Quimica e Farmaceutica Nikkho do Brasil Ltda

2007-08 Healthy Billion journey began with an aim to cross sales of $1bn by 2010-11

2007-08 Zydus entered research collaboration with Prolong

2008-09 Acquired Laboratorios Combix, Spain, Simayla Pharma of South Africa and Etna Biotech of Italy

2008-09 SPEED – Initiative towards streamlining supply chain process – Creation of GDSO

2008-09 Entered segments of Nutraceutical, Rheumatology, COPD & Hospitals – Through specialized divisions / TF

2009-10 Launched first formulation in India on Nano technology platform – Oxalgin Nanogel

2010-11 Entered into a strategic agreement with Abbott for commercializing branded generics in emerging markets

2010-11 Launched Vaxiflu – S, India’s 1st H1N1 vaccine

2010-11 Zydus Wellness Ltd. (ZWL) which spearheads the Zydus group’s presence in the consumer healthcare market listed as Asia’s 200 ‘Best under a Billion’ by Forbes.

2010-11

Zydus declared as the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.

2010-11 Entered into a 50:50 JV with Bayer to set up a new marketing company

2010-11 Achieved the goal of the Healthy Billion – becoming a Billion Dollar company

2011-12 Entered into an agreement to acquire the assets of the US based pharmaceutical company Nesher Pharmaceuticals Inc.

2011-12 The group’s formulations manufacturing plant at Baddi, Himachal Pradesh received approval from the USFDA.

2011-12 Made a foray into the ophthalmology segment by setting up a speciality division, Zydus Occucare.

2011-12 Acquired German company, Bremer Pharma GmbH, from ICICI Venture, to gain a global footprint in the animal healthcare business.

2011-12 Acquired 100% stake in Biochem, one of the top 40 pharma companies in India

2011-12 Signed an agreement with Microbix Biosystems Inc., to market the Thrombolytic drug, Urokinase in the North America

13

Emergence as a global healthcare group with operations

across 4 continents, robust NME pipeline, and a mission

to create healthier communities globally

2012 and beyond

2012-13 Beyond the Billion goal flagged off. The aim is post revenues of over $3bn by 2015 2012-13 VICA – the pillars to support the BTB aspiration launched. The four pillars stand for

Value Creation, Innovation, Collaboration and Accountability 2012-13 Launched PRISM 2, the cost optimisation programme which has identified savings

of over Rs. 200 crores spread across three waves 2012-13 Zydus Innovation Farm launched to plant, nurture and harvest ideas in the

organisation. Over 2000 ideas planted in the first 6 months 2012-13 Circles of Collaboration launched with over 50 Service Level Agreements signed to

facilitate cross functional efficiency 2012-13 VICA-BTB Value Days launched across the Zydus World to align organisational

priorities 2012-13 A total of over 114 new products launched during the year of which 31 were first in

India launches 2012-13 In the year 2012, 37 ANDAs were filed of which 12 have been approved taking the

cumulative to 170 filings and 75 approvals.

Our acquisition trail

Zydus Cadila Today: A global, mid-sized Pharma company

~60 years Operational experience

300+ products Registered annually

for US, EU, Japan and emerging mkts.

20+ mfg. sites Producing >12

bn pills annually

$ 1 bn + Global Revenues

11th largest Generic co. In US in

terms of prescriptions

Among top 5 Pharmaceutical

Companies in India

650+ patents Filed globally

$ 3 bn + Market Cap

20 brands Among top 300 brands in India

8 NCE programmes In pipeline, at various stages of clinical trials

17 Biosimilars In pipeline, apart from

2 novel biologics

~25% CAGR In Sales and Net Worth

(FY ‘06 – FY ‘11)

~6% of sales Spent on R&D annually

>35% CAGR In Net Profits

(FY ‘06 – FY ‘11)

15,000+ employees Across the globe, with

>1050 for R&D